Search

Your search keyword '"Andersen, Mads Hald"' showing total 673 results
Start Over Author "Andersen, Mads Hald"
673 results on '"Andersen, Mads Hald"'

5. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Author

Kjeldsen, Julie Westerlin, Lorentzen, Cathrine Lund, Martinenaite, Evelina, Ellebaek, Eva, Donia, Marco, Holmstroem, Rikke Boedker, Klausen, Tobias Wirenfeldt, Madsen, Cecilie Oelvang, Ahmed, Shamaila Munir, Weis-Banke, Stine Emilie, Holmström, Morten Orebo, Hendel, Helle Westergren, Ehrnrooth, Eva, Zocca, Mai-Britt, Pedersen, Ayako Wakatsuki, Andersen, Mads Hald, and Svane, Inge Marie

Published
2021
Full Text
View/download PDF

6. Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes.

Author

Hulen, Thomas Morgan, Friese, Christina, Kristensen, Nikolaj Pagh, Granhøj, Joachim Stoltenborg, Borch, Troels Holz, Peeters, Marlies J. W., Donia, Marco, Andersen, Mads Hald, Hadrup, Sine Reker, Svane, Inge Marie, and Met, Özcan

Subjects
TUMOR antigens, TUMOR-infiltrating immune cells, DEATH receptors, GENETIC barcoding, CELLULAR therapy
Abstract

Checkpoint inhibition (CPI) therapy and adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL-based ACT) are the two most effective immunotherapies for the treatment of metastatic melanoma. While CPI has been the dominating therapy in the past decade, TIL-based ACT is beneficial for individuals even after progression on previous immunotherapies. Given that notable differences in response have been made when used as a subsequent treatment, we investigated how the qualities of TILs changed when the ex vivo microenvironment of intact tumor fragments were modulated with checkpoint inhibitors targeting programmed death receptor 1 (PD-1) and cytotoxic Tlymphocyte-associated protein 4 (CTLA-4). Initially, we show that unmodified TILs from CPI-resistant individuals can be produced, are overwhelmingly terminally differentiated, and are capable of responding to tumor. We then investigate these properties in ex vivo checkpoint modulated TILs finding that that they retain these qualities. Lastly, we confirmed the specificity of the TILs to the highest responding tumor antigens, and identified this reactivity resides largely in CD39+CD69+ terminally differentiated populations. Overall, we found that anti-PD-1 will alter the proliferative capacity while anti-CTLA4 will influence breadth of antigen specificity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Author

Kjeldsen, Julie Westerlin, Lorentzen, Cathrine Lund, Martinenaite, Evelina, Ellebaek, Eva, Donia, Marco, Holmstroem, Rikke Boedker, Klausen, Tobias Wirenfeldt, Madsen, Cecilie Oelvang, Ahmed, Shamaila Munir, Weis-Banke, Stine Emilie, Holmström, Morten Orebo, Hendel, Helle Westergren, Ehrnrooth, Eva, Zocca, Mai-Britt, Pedersen, Ayako Wakatsuki, Andersen, Mads Hald, and Svane, Inge Marie

Published
2022
Full Text
View/download PDF

12. Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms

Author

Hasselbalch, Hans Carl, primary, Junker, Peter, additional, Skov, Vibe, additional, Kjær, Lasse, additional, Knudsen, Trine A., additional, Larsen, Morten Kranker, additional, Holmström, Morten Orebo, additional, Andersen, Mads Hald, additional, Jensen, Christina, additional, Karsdal, Morten A., additional, and Willumsen, Nicholas, additional

Published
2023
Full Text
View/download PDF

13. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow

Author

Holmström, Morten Orebo, primary, Andersen, Morten, additional, Traynor, Sofie, additional, Ahmad, Shamaila Munir, additional, Lisle, Thomas Landkildehus, additional, Handlos Grauslund, Jacob, additional, Skov, Vibe, additional, Kjær, Lasse, additional, Ottesen, Johnny T., additional, Gjerstorff, Morten Frier, additional, Hasselbalch, Hans Carl, additional, and Andersen, Mads Hald, additional

Published
2023
Full Text
View/download PDF

14. Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Author

Hulen, Thomas Morgan, primary, Friese, Christina, additional, Kristensen, Nikolaj Pagh, additional, Granhøj, Joachim Stoltenborg, additional, Borch, Troels Holz, additional, Peeters, Marlies J. W., additional, Donia, Marco, additional, Andersen, Mads Hald, additional, Hadrup, Sine Reker, additional, Svane, Inge Marie, additional, and Met, Özcan, additional

Published
2023
Full Text
View/download PDF

15. Survivin

Author

Andersen, Mads Hald, Becker, Jürgen, and Marshall, John L., editor

Published
2017
Full Text
View/download PDF

19. Supplementary Figure from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

Author

Nandre, Rahul, primary, Verma, Vivek, primary, Gaur, Pankaj, primary, Patil, Veerupaxagouda, primary, Yang, Xingdong, primary, Ramlaoui, Zainab, primary, Shobaki, Nour, primary, Andersen, Mads Hald, primary, Pedersen, Ayako Wakatsuki, primary, Zocca, Mai-Britt, primary, Mkrtichyan, Mikayel, primary, Gupta, Seema, primary, and Khleif, Samir N., primary

Published
2023
Full Text
View/download PDF

20. Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

Author

Peeters, Marlies J.W., primary, Dulkeviciute, Donata, primary, Draghi, Arianna, primary, Ritter, Cathrin, primary, Rahbech, Anne, primary, Skadborg, Signe K., primary, Seremet, Tina, primary, Carnaz Simões, Ana Micaela, primary, Martinenaite, Evelina, primary, Halldórsdóttir, Hólmfridur R., primary, Andersen, Mads Hald, primary, Olofsson, Gitte Holmen, primary, Svane, Inge Marie, primary, Rasmussen, Lene Juel, primary, Met, Özcan, primary, Becker, Jürgen C., primary, Donia, Marco, primary, Desler, Claus, primary, and thor Straten, Per, primary

Published
2023
Full Text
View/download PDF

21. Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

Author

Aaboe Jørgensen, Mia, primary, Ugel, Stefano, primary, Linder Hübbe, Mie, primary, Carretta, Marco, primary, Perez-Penco, Maria, primary, Weis-Banke, Stine Emilie, primary, Martinenaite, Evelina, primary, Kopp, Katharina, primary, Chapellier, Marion, primary, Adamo, Annalisa, primary, De Sanctis, Francesco, primary, Frusteri, Cristina, primary, Iezzi, Manuela, primary, Zocca, Mai-Britt, primary, Hargbøll Madsen, Daniel, primary, Wakatsuki Pedersen, Ayako, primary, Bronte, Vincenzo, primary, and Andersen, Mads Hald, primary

Published
2023
Full Text
View/download PDF

22. Table S2 from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

Author

Peeters, Marlies J.W., primary, Dulkeviciute, Donata, primary, Draghi, Arianna, primary, Ritter, Cathrin, primary, Rahbech, Anne, primary, Skadborg, Signe K., primary, Seremet, Tina, primary, Carnaz Simões, Ana Micaela, primary, Martinenaite, Evelina, primary, Halldórsdóttir, Hólmfridur R., primary, Andersen, Mads Hald, primary, Olofsson, Gitte Holmen, primary, Svane, Inge Marie, primary, Rasmussen, Lene Juel, primary, Met, Özcan, primary, Becker, Jürgen C., primary, Donia, Marco, primary, Desler, Claus, primary, and thor Straten, Per, primary

Published
2023
Full Text
View/download PDF

23. Data from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

Author

Nandre, Rahul, primary, Verma, Vivek, primary, Gaur, Pankaj, primary, Patil, Veerupaxagouda, primary, Yang, Xingdong, primary, Ramlaoui, Zainab, primary, Shobaki, Nour, primary, Andersen, Mads Hald, primary, Pedersen, Ayako Wakatsuki, primary, Zocca, Mai-Britt, primary, Mkrtichyan, Mikayel, primary, Gupta, Seema, primary, and Khleif, Samir N., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

Author

Peeters, Marlies J.W., primary, Dulkeviciute, Donata, primary, Draghi, Arianna, primary, Ritter, Cathrin, primary, Rahbech, Anne, primary, Skadborg, Signe K., primary, Seremet, Tina, primary, Carnaz Simões, Ana Micaela, primary, Martinenaite, Evelina, primary, Halldórsdóttir, Hólmfridur R., primary, Andersen, Mads Hald, primary, Olofsson, Gitte Holmen, primary, Svane, Inge Marie, primary, Rasmussen, Lene Juel, primary, Met, Özcan, primary, Becker, Jürgen C., primary, Donia, Marco, primary, Desler, Claus, primary, and thor Straten, Per, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

Author

Aaboe Jørgensen, Mia, primary, Ugel, Stefano, primary, Linder Hübbe, Mie, primary, Carretta, Marco, primary, Perez-Penco, Maria, primary, Weis-Banke, Stine Emilie, primary, Martinenaite, Evelina, primary, Kopp, Katharina, primary, Chapellier, Marion, primary, Adamo, Annalisa, primary, De Sanctis, Francesco, primary, Frusteri, Cristina, primary, Iezzi, Manuela, primary, Zocca, Mai-Britt, primary, Hargbøll Madsen, Daniel, primary, Wakatsuki Pedersen, Ayako, primary, Bronte, Vincenzo, primary, and Andersen, Mads Hald, primary

Published
2023
Full Text
View/download PDF

26. Data from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Author

Donia, Marco, primary, Harbst, Katja, primary, van Buuren, Marit, primary, Kvistborg, Pia, primary, Lindberg, Mattias F., primary, Andersen, Rikke, primary, Idorn, Manja, primary, Munir Ahmad, Shamaila, primary, Ellebæk, Eva, primary, Mueller, Anja, primary, Fagone, Paolo, primary, Nicoletti, Ferdinando, primary, Libra, Massimo, primary, Lauss, Martin, primary, Hadrup, Sine Reker, primary, Schmidt, Henrik, primary, Andersen, Mads Hald, primary, thor Straten, Per, primary, Nilsson, Jonas A., primary, Schumacher, Ton N., primary, Seliger, Barbara, primary, Jönsson, Göran, primary, and Svane, Inge Marie, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure S1-S5 from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Author

Donia, Marco, primary, Harbst, Katja, primary, van Buuren, Marit, primary, Kvistborg, Pia, primary, Lindberg, Mattias F., primary, Andersen, Rikke, primary, Idorn, Manja, primary, Munir Ahmad, Shamaila, primary, Ellebæk, Eva, primary, Mueller, Anja, primary, Fagone, Paolo, primary, Nicoletti, Ferdinando, primary, Libra, Massimo, primary, Lauss, Martin, primary, Hadrup, Sine Reker, primary, Schmidt, Henrik, primary, Andersen, Mads Hald, primary, thor Straten, Per, primary, Nilsson, Jonas A., primary, Schumacher, Ton N., primary, Seliger, Barbara, primary, Jönsson, Göran, primary, and Svane, Inge Marie, primary

Published
2023
Full Text
View/download PDF

28. Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

Author

Iversen, Trine Zeeberg, primary, Engell-Noerregaard, Lotte, primary, Ellebaek, Eva, primary, Andersen, Rikke, primary, Larsen, Stine Kiaer, primary, Bjoern, Jon, primary, Zeyher, Claus, primary, Gouttefangeas, Cécile, primary, Thomsen, Birthe Moerk, primary, Holm, Bente, primary, thor Straten, Per, primary, Mellemgaard, Anders, primary, Andersen, Mads Hald, primary, and Svane, Inge Marie, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figures 1-6 and Supplementary Table 1 from Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

Author

Andersen, Rikke, primary, Donia, Marco, primary, Ellebaek, Eva, primary, Borch, Troels Holz, primary, Kongsted, Per, primary, Iversen, Trine Zeeberg, primary, Hölmich, Lisbet Rosenkrantz, primary, Hendel, Helle Westergren, primary, Met, Özcan, primary, Andersen, Mads Hald, primary, thor Straten, Per, primary, and Svane, Inge Marie, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Methods from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Author

Donia, Marco, primary, Harbst, Katja, primary, van Buuren, Marit, primary, Kvistborg, Pia, primary, Lindberg, Mattias F., primary, Andersen, Rikke, primary, Idorn, Manja, primary, Munir Ahmad, Shamaila, primary, Ellebæk, Eva, primary, Mueller, Anja, primary, Fagone, Paolo, primary, Nicoletti, Ferdinando, primary, Libra, Massimo, primary, Lauss, Martin, primary, Hadrup, Sine Reker, primary, Schmidt, Henrik, primary, Andersen, Mads Hald, primary, thor Straten, Per, primary, Nilsson, Jonas A., primary, Schumacher, Ton N., primary, Seliger, Barbara, primary, Jönsson, Göran, primary, and Svane, Inge Marie, primary

Published
2023
Full Text
View/download PDF

37. First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer

Author

Mørk, Sofie Kirial, primary, Kongsted, Per, additional, Westergaard, Marie Christine Wulff, additional, Albieri, Benedetta, additional, Granhøj, Joachim Stoltenborg, additional, Donia, Marco, additional, Martinenaite, Evelina, additional, Holmström, Morten Orebo, additional, Madsen, Kasper, additional, Kverneland, Anders H., additional, Kjeldsen, Julie Westerlin, additional, Holmstroem, Rikke Boedker, additional, Lorentzen, Cathrine Lund, additional, Nørgaard, Nis, additional, Andreasen, Lars Vibe, additional, Wood, Grith Krøyer, additional, Christensen, Dennis, additional, Klausen, Michael Schantz, additional, Hadrup, Sine Reker, additional, thor Straten, Per, additional, Andersen, Mads Hald, additional, and Svane, Inge Marie, additional

Published
2023
Full Text
View/download PDF

38. Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy

Author

Mortensen, Rasmus Erik Johansson, primary, Holmström, Morten Orebo, additional, Lisle, Thomas Landkildehus, additional, Hasselby, Jane P, additional, Willemoe, Gro L, additional, Met, Özcan, additional, Marie Svane, Inge, additional, Johansen, Julia, additional, Nielsen, Dorte L, additional, Chen, Inna M, additional, and Andersen, Mads Hald, additional

Published
2023
Full Text
View/download PDF

39. Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome

Author

Willerslev-Olsen, Andreas, Buus, Terkild B., Nastasi, Claudia, Blümel, Edda, Gluud, Maria, Bonefeld, Charlotte M., Geisler, Carsten, Lindahl, Lise M., Vermeer, Maarten, Wasik, Mariusz A., Iversen, Lars, Becker, Jürgen C., Andersen, Mads Hald, Gjerdrum, Lise M. R., Litvinov, Ivan V., Litman, Thomas, Krejsgaard, Thorbjørn, Woetmann, Anders, and Ødum, Niels

Published
2020
Full Text
View/download PDF

42. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

Author

Grauslund, Jacob Handlos, primary, Holmström, Morten Orebo, additional, Martinenaite, Evelina, additional, Lisle, Thomas Landkildehus, additional, Glöckner, Hannah Jorinde, additional, El Fassi, Daniel, additional, Klausen, Uffe, additional, Mortensen, Rasmus E. J., additional, Jørgensen, Nicolai, additional, Kjær, Lasse, additional, Skov, Vibe, additional, Svane, Inge Marie, additional, Hasselbalch, Hans Carl, additional, and Andersen, Mads Hald, additional

Published
2023
Full Text
View/download PDF

44. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer

Author

Perez-Penco, Maria, primary, Weis-Banke, Stine Emilie, additional, Schina, Aimilia, additional, Siersbæk, Majken, additional, Hübbe, Mie Linder, additional, Jørgensen, Mia Aaboe, additional, Lecoq, Inés, additional, Lara de la Torre, Lucia, additional, Bendtsen, Simone Kloch, additional, Martinenaite, Evelina, additional, Holmström, Morten Orebo, additional, Madsen, Daniel Hargbøl, additional, Donia, Marco, additional, Ødum, Niels, additional, Grøntved, Lars, additional, and Andersen, Mads Hald, additional

Published
2022
Full Text
View/download PDF

46. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow.

Author

Orebo Holmström, Morten, Andersen, Morten, Traynor, Sofie, Munir Ahmad, Shamaila, Landkildehus Lisle, Thomas, Handlos Grauslund, Jacob, Skov, Vibe, Kjær, Lasse, Ottesen, Johnny T., Frier Gjerstorff, Morten, Hasselbalch, Hans Carl, and Andersen, Mads Hald

Subjects
T cells, CANCER vaccines, BONE marrow, MYELOPROLIFERATIVE neoplasms, BONE marrow cells
Abstract

Background: Therapeutic cancer vaccination against mutant calreticulin (CALR) in patients with CALR-mutant (CALRmut) myeloproliferative neoplasms (MPN) induces strong T-cell responses against mutant CALR yet fails to demonstrate clinical activity. Infiltration of tumor specific T cells into the tumor microenvironment is needed to attain a clinical response to therapeutic cancer vaccination. Aim: Determine if CALRmut specific T cells isolated from vaccinated patients enrich in the bone marrow upon completion of vaccination and explore possible explanations for the lack of enrichment. Methods: CALRmut specific T cells from four of ten vaccinated patients were expanded, enriched, and analyzed by T-cell receptor sequencing (TCRSeq). The TCRs identified were used as fingerprints of CALRmut specific T cells. Bone marrow aspirations from the four patients were acquired at baseline and at the end of trial. T cells were enriched from the bone marrow aspirations and analyzed by TCRSeq to identify the presence and fraction of CALRmut specific T cells at the two different time points. In silico calculations were performed to calculate the ratio between transformed cells and effector cells in patients with CALRmut MPN. Results: The fraction of CALRmut specific T cells in the bone marrow did not increase upon completion of the vaccination trial. In general, the T cell repertoire in the bone marrow remains relatively constant through the vaccination trial. The enriched and expanded CALRmut specific T cells recognize peripheral blood autologous CALRmut cells. In silico analyses demonstrate a high imbalance in the fraction of CALRmut cells and CALRmut specific effector T-cells in peripheral blood. Conclusion: CALRmut specific T cells do not enrich in the bone marrow after therapeutic cancer peptide vaccination against mutant CALR. The specific T cells recognize autologous peripheral blood derived CALRmut cells. In silico analyses demonstrate a high imbalance between the number of transformed cells and CALRmut specific effector T-cells in the periphery. We suggest that the high burden of transformed cells in the periphery compared to the number of effector cells could impact the ability of specific T cells to enrich in the bone marrow. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV

Author

Klausen, Uffe, primary, Grauslund, Jacob Handlos, additional, Jørgensen, Nicolai Grønne Dahlager, additional, Ahmad, Shamaila Munir, additional, Jonassen, Merete, additional, Weis-Banke, Stine Emilie, additional, Martinenaite, Evelina, additional, Pedersen, Lone Bredo, additional, Lisle, Thomas Landkildehus, additional, Gang, Anne Ortved, additional, Enggaard, Lisbeth, additional, Hansen, Morten, additional, Holmström, Morten Orebo, additional, Met, Özcan, additional, Svane, Inge Marie, additional, Niemann, Carsten Utoft, additional, Pedersen, Lars Møller, additional, and Andersen, Mads Hald, additional

Published
2022
Full Text
View/download PDF

50. Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells

Author

Weis-Banke, Stine Emilie, primary, Lisle, Thomas Landkildehus, additional, Perez-Penco, Maria, additional, Schina, Aimilia, additional, Hübbe, Mie Linder, additional, Siersbæk, Majken, additional, Holmström, Morten Orebo, additional, Jørgensen, Mia Aaboe, additional, Marie Svane, Inge, additional, Met, Özcan, additional, Ødum, Niels, additional, Madsen, Daniel Hargbøl, additional, Donia, Marco, additional, Grøntved, Lars, additional, and Andersen, Mads Hald, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results